masshightech.com | Submitted by Jordanna, 03.05.10
The ALS Therapy Development Institute and Oxford BioMedica announced today they are advancing to a second phase their collaboration on a preclinical gene therapy candidate for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).The collaboration is an effort to advance the development of Oxford BioMedica’s preclinical gene therapy candidate and to evaluate other gene-based strategies for the treatment of ALS.
forbes.com | Submitted by Jordanna, 09.25.08
Researchers have implicated a new, yet rare, genetic mutation in the development of amyotrophic lateral sclerosis (ALS).